Gupta RK, Lucas SB, Fielding KL, Lawn SD. Prevalence of tuberculosis in post-mortem studies of HIVinfected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987–2002. doi: 10.1097/QAD.0000000000000802.
Political Declaration on the High-Level Meeting on the Fight Against Tuberculosis “Advancing science, finance and innovation, and their benefits, to urgently end the global tuberculosis epidemic, in particular by ensuring equitable access to prevention, testing, treatment and care”. New York: United Nations; 2023 (https:// documents-dds-ny.un.org/doc/UNDOC/GEN/N23/306/91/PDF/N2330691.pdf, accessed 17 January 2024).
WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012 (https://apps.who.int/iris/handle/10665/44789, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/352522, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331170, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/365308, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340255, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342331, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – tests for tuberculosis infection. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/362936, accessed 21 August 2023).
WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/353829, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis. Module 4: treatment – tuberculosis care and support. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/353399, accessed 31 August 2023).
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 31 August 2023).
Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/112360, accessed 31 August 2023).
Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/255884, accessed 31 August 2023).
Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340190, accessed 31 August 2023).
Framework for collaborative action on tuberculosis and comorbidities. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/361989, accessed 31 August 2023).
Eang MT, Vun MC, Eam KK, Sovannarith S, Sopheap S, Bora N et al. The multi-step process of building TB/HIV collaboration in Cambodia. Health Res Policy and Syst. 2012;10:34. doi: 10.1186/1478-4505-10-34.
Okot-Chono R, Mugisha F, Adatu F, Madraa E, Dlodlo R, Fujiwara P. Health system barriers affecting the implementation of collaborative TB–HIV services in Uganda. Int J Tuberc Lung Dis. 2009;13:955-61. PMID: 19723374.
Multisectoral accountability framework to accelerate progress to end tuberculosis by 2030. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/331934, accessed 31 August 2023).
Guidance for the surveillance of drug resistance in tuberculosis, 6th ed. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/339760, accessed 31 August 2023).
WHO consolidated guidelines on tuberculosis data generation and use. Module 3: national tuberculosis prevalence surveys, World Health Organization, in press, 2024.
Mitchell EMH, van den Broek J, Wandwalo E, Colvin C. Lessons from loss: A guide to conducting TB patient mortality audits using a patient-centered approach. The Hague: KNCV Tuberculosis Foundation TB CARE I; 2012 (https://www.challengetb.org/publications/tools/hss/Lessons_from_Loss.pdf, accessed 27 January 2023).
Harmonized health facility assessment (HHFA): comprehensive guide. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/365534, accessed 31 August 2023).
Guide to develop a national action plan on public-private mix for tuberculosis prevention and care. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/361884, accessed 31 August 2023).
People-centred framework for tuberculosis programme planning and prioritization: user guide. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/329472, accessed 31 August 2023).
WHO operational handbook on tuberculosis. Module 4: treatment – tuberculosis care and support. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/359147, accessed 31 August 2023).
Siddiqi K, Keding A, Marshall A-M, Dogar O, Li J, Huque R et al. Effect of quitting smoking on health outcomes during treatment for tuberculosis: secondary analysis of the TB & Tobacco Trial. Thorax. 2022;77(1):74–78. doi: 10.1136/THORAXJNL-2020-215926.
Pasha A, Siddiqui H, Ali S, Brooks MB, Maqbool NR, Khan AJ. Impact of integrating mental health services within existing tuberculosis treatment facilities. Med Access Point Care. 2021;5. doi: 10.1177/23992026211011314.
Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-effectiveness of community-based TB/HIV screening and linkage to care in rural South Africa. PLoS One. 2016;11(12):e0165614. doi: 10.1371/ journal.pone.0165614.
Williams AO, Makinde OA, Ojo M. Community-based management versus traditional hospitalization in treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. Glob Health Res Policy. 2016;1(10). doi: 10.1186/S41256-016-0010-Y.
Accessibility and integration of HIV, TB and harm reduction services for people who inject drugs in Portugal: a rapid assessment. Copenhagen: World Health Organization Regional Office for Europe; 2012 (https://researchonline.lshtm.ac.uk/id/eprint/1805470, accessed 31 August 2023).
Country case studies on primary health care: China: multidisciplinary teams and integrated service delivery across levels of care. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/326085, accessed 31 August 2023).
Legido-Quigley H, Montgomery CM, Khan P, Atun R, Fakoya A, Getahun H et al. Integrating tuberculosis and HIV services in low- and middle-income countries: a systematic review. Trop Med Int Health. 2013;18(2):199– 211. doi: 10.1111/tmi.12029.
Herce ME, Morse J, Luhanga D, Harris J, Smith HJ, Besa S et al. Integrating HIV care and treatment into tuberculosis clinics in Lusaka, Zambia: results from a before-after quasi-experimental study. BMC Infect Dis. 2018;18(536). doi: 10.1186/S12879-018-3392-2.
Burnett SM, Zawedde-Muyanja S, Hermans SM, Weaver MR, Colebunders R, Manabe YC. Effect of TB/ HIV integration on TB and HIV indicators in rural Ugandan health facilities. Acquir Immune Defic Syndr. 2018;79(5):605–11. doi: 10.1097/QAI.0000000000001862.
Brown C, Kerschberger B, Boulle A, Cotzee D, Post F, Azevedo V. TB and HIV service integration within a South African primary health care setting reduces the time to ART initiation without negatively impacting TB outcomes. In: Proceedings. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011), 27 February–2 March 2011, Boston.
Bygrave H, Trivino L, Makakole L. TB/HIV integration: lessons learned from implementation of a TB/HIV “one stop shop” at primary health care clinics in rural Lesotho. In: Proceedings. XVIII International AIDS Conference, Vienna, 2010.
Management of collaborative TB/HIV activities: training for managers at the national and subnational levels. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/handle/10665/69374, accessed 31 August 2023).
WHO guideline on health policy and system support to optimize community health worker programmes. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/275474, accessed 31 August 2023).
Datiko DG, Lindtjørn B. Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS One. 2009;4(5):e5443. doi: 10.1371/journal. pone.0005443.
Corbett EL, Bandason T, Duong T, Dauya E, Makamure B, Churchyard GJ et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a cluster-randomised trial. Lancet. 2010;376(9748):1244–53. doi: 10.1016/S0140-6736(10)61425-0.
Lugada E, Levin J, Abang B, Mermin J, Mugalanzi E, Namara G et al. Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr. 2010;55(2):245–52. doi: 10.1097/QAI.0b013e3181e9e069.
Miti S, Mfungwe V, Reijer P, Maher D. Integration of tuberculosis treatment in a community-based home care programme for persons living with HIV/AIDS in Ndola, Zambia. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1):S92–8. PMID: 12971660.
Wandwalo E, Kapalata N, Tarimo E, Corrigan CB, Morkve O. Collaboration between the national tuberculosis programme and a non governmental organisation in TB/HIV care at a district level: experience from Tanzania. Afr Health Sci. 2004;4(2):109–114. PMID: 15477189.
Lindsay BR, Mwango L, Toeque M-G, Malupande SL, Nkhuwa E, Moonga CN et al. Peer community health workers improve HIV testing and ART linkage among key populations in Zambia: retrospective observational results from the Z-CHECK project, 2019–2020. J Int AIDS Soc. 2022;25(11):e26030. doi: 10.1002/JIA2.26030.
Sinanovic E, Floyd K, Dudley L, Azevedo V, Grant R, Maher D. Cost and cost-effectiveness of communitybased care for tuberculosis in Cape Town, South Africa. Int J Tuberc Lung Dis. 2003;7:S56–62. PMID: 12971655
Okello D, Floyd K, Adatu F, Odeke R, Gargioni G. Cost and cost-effectiveness of community-based care for tuberculosis patients in rural Uganda. Int J Tuberc Lung Dis. 2003;7(9 Suppl 1). PMID: 12971657.
Creese A, Floyd K, Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet. 2002;359(9318):1635–42. doi: 10.1016/S0140-6736(02)08595-1.
Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2022. (https://apps.who.int/iris/handle/10665/360601, accessed 31 August 2023).
Getahun H, Baddeley A, Raviglione M. Managing tuberculosis in people who use and inject illicit drugs. Bull World Health Organ. 2013;91(2):154. doi: 10.2471/BLT.13.117267.
Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102. doi: 10.1016/ S0140-6736(16)30466-4.
Salifu RS, Hlongwana KW. Barriers and facilitators to bidirectional screening of TB-DM in Ghana: healthcare workers’ perspectives. PLoS One. 2020;15(7). doi: 10.1371/journal.pone.0235914.
Contreras CC, Millones AK, Cruz JS, Aguilar M, Clendenes M, Toranzo M et al. Addressing tuberculosis patients’ medical and socio-economic needs: a comprehensive programmatic approach. Trop Med Int Health. 2017;22(4):505–11. doi: 10.1111/TMI.12844.
Degefa MG, Bezabih AM, Kahsay ZH, Belachew AB. Barriers and facilitators of nutrition assessment, counseling, and support for tuberculosis patients: a qualitative study. BMC Nutr. 2021;7(1):58. doi: 10.1186/ s40795-021-00463-x.
Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43(6):1763–75. doi: 10.1183/09031936.00193413.
A guide to monitoring and evaluation for collaborative TB/HIV activities – 2015 revision. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/150627, accessed 31 August 2023).
Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331697, accessed 31 August 2023).
Operational framework for primary health care: transforming vision into action. Geneva: World Health Organization, United Nations Children’s Fund (UNICEF); 2020 (https://apps.who.int/iris/handle/10665/337641, accessed 31 August 2023).
Continuity and coordination of care: a practice brief to support implementation of the WHO Framework on integrated people-centred health services. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/274628, accessed 31 August 2023).
Handbook for the use of digital technologies to support tuberculosis medication adherence. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/259832, accessed 31 August 2023).
University of Oslo, UiO: HISP Centre, DHIS2 [website] (https://dhis2.org, accessed 31 August 2023).
Ethics guidance for the implementation of the End TB strategy. Geneva: World Health Organization; 2017 (https://iris.who.int/handle/10665/254820, accessed 31 August 2023).
Sculier D, Getahun H, Lienhardt C. Improving the prevention, diagnosis and treatment of TB among people living with HIV: the role of operational research. J Int AIDS Soc. 2011;14(Suppl 1):S5S. doi: 10.1186/1758- 2652-14-S1-S5.
Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://iris.who.int/handle/10665/44472, accessed 31 August 2023).
Bjerrum S, Bonsu F, Hanson-Nortey NN, Kenu E, Johansen IS, Andersen AB et al. Tuberculosis screening in patients with HIV: use of audit and feedback to improve quality of care in Ghana. Glob Health Action. 2016;9:32390. doi: 10.3402/gha.v9.32390.
Der JB, Grint DJ, Narh CT, Bonsu F, Grant AD. Missed opportunities for tuberculosis investigation in a municipal hospital in Ghana: evidence from patient exit interviews. Trans R Soc Trop Med Hyg. 2021;115(1):43–50. doi: 10.1093/trstmh/traa080.
WHO operational handbook on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/340256, accessed 31 August 2023).
Determining the local calibration of computer-assisted detection (CAD) thresholds and other parameters: a toolkit to support the effective use of CAD for TB screening. Geneva: World Health Organization & UNICEF/ UNDP/World Bank/WHO Special Programme for Research Training in Tropical Diseases; 2021 (https://apps.who.int/iris/handle/10665/345925, accessed 31 August 2023).
Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO’s recommended foursymptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(9):e515-e23. doi: 10.1016/S2352-3018(18)30137-1.
Camelique O, Scholtissen S, Dousset J-P, Bonnet M, Bastard M, Hewison C. Mobile community-based active case-finding for tuberculosis among older populations in rural Cambodia. Int J Tuberc Lung Dis. 2019;23(10):1107–14. doi: 10.5588/IJTLD.18.0611.
Chest radiography in tuberculosis detection: summary of current WHO recommendations and guidance on programmatic approaches. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/252424, accessed 31 August 2023).
Sabur NF, Esmail A, Brar MS, Dheda K. Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer? BMC Infect Dis. 2017;17(1):803. doi: 10.1186/S12879-017-2914-7.
WHO operational handbook on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342369, accessed 31 August 2023).
Molecular assays intended as initial tests for the diagnosis of pulmonary and extrapulmonary TB and rifampicin resistance in adults and children: rapid communication. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/330395, accessed 31 August 2023).
Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020. Geneva: World Health Organization; 2013 (https://apps.who.int/iris/handle/10665/79199, accessed 31 August 2023).
Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis. 1993;148(5):1292–7. doi: 10.1164/AJRCCM/148.5.1292.
Naing C, Mak JW, Maung M, Wong SF, Kassim AIBM. Meta-analysis: the association between HIV infection and extrapulmonary tuberculosis. Lung. 2012;191(1):27–34. doi: 10.1007/S00408-012-9440-6.
Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings. Geneva: World Health Organization; 2007. (https://apps.who.int/iris/handle/10665/69463, accessed 31 August 2023).
Yakhelef N, Audibert M, Ferlazzo G, Sitienei J, Wanjala S, Varaine F et al. Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis. PLoS One. 2020;15(1):e0227138. doi: /10.1371/journal.pone.0227138.
Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakidis P et al. Mortality in adults with multidrugresistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet. 2020;396(10248):402–11. doi: 10.1016/S0140-6736(20)31316-7
Sultana ZZ, UI Hoque F, Beyene J, Akhlak-Ul-Islam T, Khan HR, Ahmed S et al. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2021;21(1):51. doi: 10.1186/ s12879-020-05749-2.
Daftary A, Padayatchi N, O’Donnell M. Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health. 2014;9(9):1107–16. doi: 10.1080/17441692.2014.934266.
Modongo C, Wang Q, Dima M, Matsiri O, Kgwaadira B, Rankgoane-Pono G et al. Clinical and virological outcomes of TB/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana. J Acquir Immune Defic Syndr. 2019;82(2):111–5. doi: 10.1097/ QAI.0000000000002126.
WHO operational handbook on tuberculosis. Module 4: treatment – drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/354548, accessed 31 August 2023).
Integrating collaborative TB and HIV services within a comprehensive package of care for people who inject drugs: consolidated guidelines. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/204484, accessed 31 August 2023).
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705–18. doi: 10.1056/NEJMoa2033400.
Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-month rifapentinemoxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis – United States, 2022. Morb Mortal Wkly Rep. 2022;71(8):285–289. doi:10.15585/mmwr.mm7108a1.
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ et al. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020;90:105938. doi: 10.1016/j.cct.2020.105938.
Post FA, Grint D, Werlinrud AM, Panteleev A, Riekstina V, Malashenkov EA et al. Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. J Infect. 2014;68(3):259–63. doi: 10.1016/j.jinf.2013.09.034.
Suchindran S, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. PLoS One. 2009;4(5):e5561. doi: doi.org/10.1371/journal.pone.0005561.
Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One. 2014;9(1):e82235. doi: 10.1371/journal. pone.0082235.
Dean AS, Zignol M, Falzon D, Getahun H, Floyd K. HIV and multidrug-resistant tuberculosis: overlapping epidemics. Eur Respir J. 2014;44(1):251–4. doi: 10.1183/09031936.00205413.
WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/365333, accessed 31 August 2023).
Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis. 1994;18(2):266–7. doi: 10.1093/clinids/18.2.266.
Bhargava A, Bhargava M. Tuberculosis deaths are predictable and preventable: comprehensive assessment and clinical care is the key. J Clin Tuberc Other Mycobact Dis. 2020;19:100155. doi: 10.1016/j.jctube.2020.100155.
Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54. doi: 10.1183/13993003.00655-2019.
Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi: 10.1371/journal.pmed.1002152.
Gupta RK, Rice B, Brown AE, Thomas HL, Zenner D, Anderson L et al. Does antiretroviral therapy reduce HIVassociated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV. 2015;2(6):e243–51. doi: 10.1016/S2352-3018(15)00063-6.
Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. doi: 10.1371/journal.pmed.1001270.
Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, N’takpé JB et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–9. doi: 10.1016/S2214-109X(17)30372-8.
Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22. doi: 10.1056/NEJMoa1507198.
WHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331525, accessed 31 August 2023).
Chaisson LH, Saraceni V, Cohn S, Seabrook D, Cavalcante SC, Chaisson RE et al. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV. AIDS. 2020;34(1):139–47. doi: 10.1097/ QAD.0000000000002398.
WHO operational handbook on tuberculosis. Module 3: diagnosis – tests for tuberculosis infection. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/363335, accessed 31 August 2023).
Churchyard G, Cárdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W et al. Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial. Ann Intern Med. 2021;174(10):1367–76. doi: 10.7326/M20-7577.
Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61(8):1322–7. doi: 10.1093/CID/CIV464.
Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69(4):1079–85. doi: 10.1093/ jac/dkt483.
Dooley KE, Savic R, Gupte A, Marzinke MA, Zhang N, Edward VA et al. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. Lancet HIV. 2020;7(6):e401–9. doi: 10.1016/S2352-3018(20)30032-1.
Sotgiu G, Matteelli A, Getahun H, Girardi E, Sañé Schepisi M, Centis R et al. Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. Eur Respir J. 2015;45:1170–3. doi: 10.1183/09031936.00216814.
Gupta A, Nayak U, Ram M, Bhosale R, Patil S, Basavraj A et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–9. doi: 10.1086/518974.
Salazar-Austin N, Hoffmann J, Cohn S, Mashabela F, Waja Z, Lala S et al. Poor obstetric and infant outcomes in human immunodeficiency virus-infected pregnant women with tuberculosis in South Africa: the Tshepiso Study. Clin Infect Dis. 2018;66(6):921–9. doi: 10.1093/CID/CIX851.
Friedland G. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S37–42. doi: 10.1097/QAI.0b013e3181f9c0b6.
Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and drug use: review and update. Clin Infect Dis. 2009;48(1):72– 82. doi: 10.1086/594126.
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009 (https://apps.who.int/iris/handle/10665/43948, accessed 31 August 2023).
McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend. 2011;118(2–3):326–34. doi: 10.1016/j.drugalcdep.2011.04.013.
Musaazi J, Sekaggya-Wiltshire C, Okoboi S, Zawedde-Muyanja S, Senkoro M, Kalema N et al. Increased uptake of tuberculosis preventive therapy (TPT) among people living with HIV following the 100-days accelerated campaign: a retrospective review of routinely collected data at six urban public health facilities in Uganda. PLoS One. 2023;18(2):e0268935. doi: 10.1371/journal.pone.0268935.
WHO consolidated guidelines on tuberculosis. Module 1: prevention – infection prevention and control. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/362508, accessed 26 September 2023).
Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/251730, accessed 31 August 2023).
WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva: World Health Organization; 2009 (https://apps.who.int/iris/handle/10665/44148, accessed 31 August 2023).
Scaling up of collaborative TB/HIV activities in concentrated HIV epidemic settings: a case study from India. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/154076, accessed 31 August 2023).
Nliwasa M, MacPherson P, Gupta-Wright A, Mwapasa M, Horton K, Odland J et al. High HIV and active tuberculosis prevalence and increased mortality risk in adults with symptoms of TB: a systematic review and meta-analyses. J Int AIDS Soc. 2018;21(7):e25162. doi: 10.1002/JIA2.25162.
Salomon A, Law S, Johnson C, Baddeley A, Rangaraj A, Singh S et al. Interventions to improve linkage along the HIV-tuberculosis care cascades in low- and middle-income countries: a systematic review and metaanalysis. PLoS One. 2022;17(5):e0267511. doi: 10.1371/journal.pone.0267511.
Consolidated guidelines on HIV testing services: 5Cs: consent, confidentiality, counselling, correct results and connection 2015. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/179870, accessed 31 August 2023).
Eaton JW, Johnson CC, Gregson S. The cost of not retesting: human immunodeficiency virus misdiagnosis in the antiretroviral therapy “test-and-offer” era. Clin Infect Diss. 2017;65(3):522–5. doi: 10.1093/CID/CIX341.
CD4 assays | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) [Internet]. Geneva: World Health Organization. (https://extranet.who.int/pqweb/whopr-category/cd4-assays, accessed 6 December 2022).
Maskew M, Brennan AT, Fox MP, Vezi L, Venter WDF, Ehrenkranz P et al. A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial. PLoS Med. 2020;17(8):e1003226. doi: 10.1371/journal.pmed.1003226.
Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G et al. Erratum: Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13(6):e1002050. doi: 10.1371/journal.pmed.1002050.
Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete, G et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13(5):e1002015. doi: 10.1371/journal.pmed.1002015.
Rosen S, Maskew M, Larson BA, Brennan AT, Tsikhutsu I, Fox MP et al. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): results from an individually randomized trial in South Africa and Kenya. PLoS Med. 2019;16(9):e1002912. doi: 10.1371/journal.pmed.1002912.
Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trial. JAMA. 2018;319(11):1103–12. doi: 10.1001/jama.2018.1818.
Tweya H, Heller T. Initiating TB treatment and ART at the same time – observations and experiences from Martin-Preuss Center, Lilongwe, Malawi.
Török ME, Yen NTB, Chau TTH, Mai NTH, Phu NH, Mai PP et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis. 2011;52(11):1374– 83. doi: 10.1093/cid/cir230.
Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251–61. doi: 10.1016/S1473-3099(10)70026-8.
Burke RM, Rickman HM, Singh V, Corbett EL, Ayles H, Jahn A et al. What is the optimum time to start antiretroviral therapy in people with HIV and tuberculosis coinfection? A systematic review and meta-analysis. J Int AIDS Soc. 2021;24(7):e25772. doi: 10.1002/2.25772.
Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIVrelated infections among adults, adolescents and children: recommendations for a public health approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145719, accessed 31 August 2023).
Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM et al. Global burden of disease of HIVassociated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–81. doi: 10.1016/ S1473-3099(17)30243-8.
Tenforde MW, Shapiro AE, Rouse B, Jarvis JN, Li T, Eshun-Wilson I et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database Syst Rev. 2018;7(7):CD005647. doi: 10.1002/14651858. CD005647.3.
Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV. 2015;2(10):e438–44. doi: 10.1016/S2352-3018(15)00137-X.
Pasquier E, Kunda J, de Beaudrap P, Loyse A, Temfack E, Molloy SF et al. Long-term mortality and disability in cryptococcal meningitis: a systematic literature review. Clin Infect Dis. 2018;66(7):1122–32. doi: 10.1093/ cid/cix870.
Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C et al. CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(Suppl_2):S152–9. doi: 10.1093/CID/CIX1143.
Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/handle/10665/357088, accessed 31 August 2023).
Beardsley J, Wolbers M, Kibengo FM, Ggayi A-BM, Kamali A, Cuc NTK et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis. N Engl J Med. 2016;374(6):542–54. doi: 10.1056/NEJMoa1509024.
Rick F, Niyibizi AA, Shroufi A, Onami K, Steele S-J, Kuleile M et al. Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: a feasibility study in rural Lesotho. PLoS One. 2017;12(9):e0183656. doi: 10.1371/journal.pone.0183656.
Adenis A, Nacher M, Hanf M, Basurko C, Dufour J, Huber F et al. Tuberculosis and histoplasmosis among human immunodeficiency virus-infected patients: a comparative study. Am J Trop Med Hyg. 2014;90(2):216– 23. doi: 10.4269/ajtmh.13-0084.
Caceres DH, Valdes A. Histoplasmosis and tuberculosis co-occurrence in people with advanced HIV. J Fungi (Basel). 2019;5(3):73. doi: 10.3390/jof5030073.
Pasqualotto AC, Quieroz-Telles F. Histoplasmosis dethrones tuberculosis in Latin America. Lancet Infect Dis. 2018;18(10):1058–60. doi: 10.1016/S1473-3099(18)30373-6.
Andes D, Pascua A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24–34. doi: 10.1128/AAC.00705-08.
Gasana M, Vandebriel G, Kabanda G, Tsiouris SJ, Justman J, Sahabo R et al. Integrating tuberculosis and HIV care in rural Rwanda. Int J Tuberc Lung Dis. 2008;12(3 Suppl 1):39–43. PMID: 18302821.
Shetty PVD, Granich RM, Patil AB, Sawant SK, Sahu S, Wares DF et al. Cross-referral between voluntary HIV counselling and testing centres and TB services, Maharashtra, India, 2003–2004. Int J Tuberc Lung Dis. 2008;12(3 Suppl 1):26-31. PMID: 18302819.
Sharma N, Khanna A, Chandra S, Basu S, Bajaj D, Sachdeva KS et al. Tuberculosis (TB) intervention model targeting mobile population of truckers in Delhi, India. Indian J Tuberc. 2019;66(3):382–7. doi: 10.1016/j. ijtb.2018.10.011.
Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Geneva: World Health Organization; 2004 (https://apps.who.int/iris/handle/10665/43107, accessed 31 August 2023).
Effectiveness of drug dependence treatment in prevention of HIV among injecting drug users. Geneva: World Health Organization; 2005 (https://apps.who.int/iris/handle/10665/43259, accessed 31 August 2023).
French PP, Latka M, Gollub EL, Rogers C, Hoover DR, Stein ZA. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis. 2003;30(5):433–9. doi: 10.1097/00007435-200305000-00010.
Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337–44. doi: 10.1097/QAI.0000000000000461.
Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1):CD003255. doi: 10.1002/14651858.CD003255.
Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics: recommendations and key considerations. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/333841, accessed 31 August 2023).